TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting
TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-d...
Continue Reading →
